TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02345161
Drug: Budesonide/Formoterol
Normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
Study: NCT02345161
Drug: Placebo to match Budesonide/Formoterol combination
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
Study: NCT02345161
Drug: Albuterol/salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
Study: NCT04303390
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: second generation cephalosporin
Study: NCT04303390
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First generation cephalosporin
Study: NCT00247481
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00247481
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00683189
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
Study: NCT00598962
Drug: Rifabutin/rifampin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04635735
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
Study: NCT04329923
Drug: Hydroxychloroquine Sulfate 400 mg twice a day
Normalized name: hydroxychloroquine sulfate 400 MG
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial compound
Study: NCT04329923
Drug: Hydroxychloroquine Sulfate 600 mg twice a day
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial compound
Study: NCT04329923
Drug: Hydroxychloroquine Sulfate 600 mg once a day
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial compound
Study: NCT00389415
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03334214
Drug: IONIS DGAT2Rx
Normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
Study: NCT00750347
Drug: Rimonabant and Paracetamol and placebo
Normalized name: codeine and paracetamol
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
Study: NCT04546256
Drug: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT02046564
Drug: ASC-01
Normalized name: ASC
DrugBank: N-acetylsulfanilyl chloride (DB12337)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01040130
Drug: Olodaterol (BI 1744)
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of low and high doses on exercise endurance time in COPD patients
Study: NCT01040130
Drug: Olodaterol (BI 1744)
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of low and high dose
Study: NCT01040130
Drug: Olodaterol (BI 1744) Placebo
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo that represents olodaterol
Study: NCT01316744
Drug: ketamine hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03054844
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine will be administered before administration of midazolam.
Study: NCT03054844
Drug: Lidocaine and midazolam (PREMIX)
Normalized name: Midazolam
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lidocaine will be administered as a mixture with midazolam.
Study: NCT03054844
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
Study: NCT00660140
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00660140
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00990015
Drug: PF-04308515
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
Study: NCT02609711
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00593112
Drug: OROS methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
Study: NCT03838848
Drug: KN046
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3mg/kg, Q2W, intravenous injection (IV)
Study: NCT03838848
Drug: KN046
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg/kg, Q2W, intravenous injection (IV)
Study: NCT03838848
Drug: KN046
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg/kg, Q3W, intravenous injection (IV)
Study: NCT03838848
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
Study: NCT03838848
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2, Q3W, intravenous injection (IV)
Study: NCT03838848
Drug: Ningetinib
Normalized name: Ningetinib
DrugBank: Ningetinib (DB16256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, QD
Study: NCT00562510
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg BID added to stable HAART
Study: NCT00692705
Drug: Radioligand (11C)AZD2995
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
Study: NCT00692705
Drug: Radioligand (11C)AZD2184
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of i.v solution. Once for AD patients respective healthy volunteers.
Study: NCT00234104
Drug: OPC-41061(Tolvaptan)
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03471910
Drug: Diosmin
Normalized name: Diosmin
DrugBank: Diosmin (DB08995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin 600mg tablet, once daily
Study: NCT03471910
Drug: Diosmin / Hesperidin
Normalized name: diosmin / hesperidin
DrugBank: Hesperidin (DB04703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin 900 mg / Hesperidin 100mg tablet, once daily
Study: NCT00949650
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed IV given once every 3 weeks for up to 6 cycles
Study: NCT00949650
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin IV given once every 3 weeks for up to 6 cycles
Study: NCT01300377
Drug: Bupivacaine / Lidocaine
Normalized name: bupivacaine / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
Study: NCT01300377
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
Study: NCT00107107
Drug: pramlintide acetate
Normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syringe vial and Pen-cartridge
Study: NCT00006246
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03240835
Drug: cisplatin and docetaxel
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles.
Study: NCT01934335
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00112138
Drug: gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02168946
Drug: Vabomere
Normalized name: Vabomere
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vabomere for IV injection, administered as a 2 g/2 g dose
Study: NCT03340493
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
Study: NCT00087204
Drug: becatecarin
Normalized name: Becatecarin
DrugBank: Becatecarin (DB06362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01852344
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mgs of methylphenidate or placebo to be administered one hour before task performance
Study: NCT02307305
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~2. Phase II (titration): POD#1\~6 (30mg for another 6 days)~3. Phase III (maintenance): POD#7\~13(60mg for 7 days)~4. Phase IV (tapering-1): POD#14\~20 (30mg for 7 days)~5. Phase V (tapering-2): POD#21\~27 (30mg another every day for 7 days)
Study: NCT02296840
Drug: Hydrocodone-Acetaminophen
Normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
Study: NCT01507545
Drug: MORAb-004
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MORAb-004 8mg per kg IV once a week
Study: NCT02035072
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2
Study: NCT02035072
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 100 mg/m2
Study: NCT02997189
Drug: OTO-104
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg dexamethasone administered intratympanically
Study: NCT02400112
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin powder administered locally, intraoperatively at site of open fracture
Study: NCT03072511
Drug: Transdermal Nicotine Patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
Study: NCT00317070
Drug: dimethyl sulfoxide
Normalized name: Dimethyl Sulfoxide
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravesical installation 50 ml
Study: NCT00233636
Drug: Iressa (Gefitinib)
Normalized name: Iressa
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01046643
Drug: Progesterone (P10) x90
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
Study: NCT01046643
Drug: Progesterone (P10) x10
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
Study: NCT01030042
Drug: Irinotecan/Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.
Study: NCT01898312
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomised controlled trial of Mifepristone and placebo comparator Triobe
Study: NCT04156646
Drug: Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
Study: NCT04156646
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
Study: NCT02443844
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical treatment for benign prostate hyperplasia
Study: NCT04110834
Drug: itraconazole gel once daily
Normalized name: clindamycin
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
Study: NCT04110834
Drug: itraconazole gel twice daily
Normalized name: clindamycin
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
Study: NCT00002423
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002423
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002423
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02893722
Drug: atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
Study: NCT00002423
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002423
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01157858
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg every day orally
Study: NCT01157858
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg every 28 days IM
Study: NCT03687034
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
Study: NCT03425799
Drug: Sodium Chloride 0.9% Inj
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Study: NCT03425799
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Study: NCT01225406
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02976467
Drug: Fulacimstat (BAY1142524)
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
Study: NCT00397228
Drug: ALTROPANE®
DrugBank: Altropane (DB04947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALTROPANE® SPECT imaging
Study: NCT04302181
Drug: Ropivacaine injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6.5cc of Ropivacaine HCl 0.5%, one time into the stellate ganglion
Study: NCT00946270
Drug: CC-4047
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg capsules daily by mouth day 1 through day 28.
Study: NCT00946270
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
Study: NCT00946270
Drug: CC-4047
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg capsules daily by mouth day 1 through 21.
Study: NCT02672839
Drug: LGD-6972 Solution
Normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of LGD-6972
Study: NCT02672839
Drug: LGD-6972 Capsules
Normalized name: LGD-6972
DrugBank: LGD-6972 (DB14779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg LGD-6972
Study: NCT00306891
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg oral dose
Study: NCT00306891
Drug: Cediranib 30 - 90 mg
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet dose escalation
Study: NCT01757457
Drug: Intracoronary administration of an abciximab bolus during primary PCI
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Study: NCT01757457
Drug: Intravenous administration of an abciximab bolus during primary PCI
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
Study: NCT00232570
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01511146
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 85 mg/m2 in 10 minutes
Study: NCT01511146
Drug: Mitomycin + Gemcitabine
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
Study: NCT01161524
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg titrated up to 8-12 mg maximum; taken once daily.
Study: NCT02499965
Drug: Ethyl Chloride Topical Aerosol Anesthetic
Normalized name: ethyl chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Study: NCT02499965
Drug: Nature's Tears Sterile Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprayed on the skin for 5-8 seconds immediately before IV cannulation
Study: NCT00072969
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02329535
Drug: Micronized progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: vaginal caps 400 mg daily up to 36 weeks of gestation
Study: NCT02365532
Drug: GS-6615
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-6615 tablets administered orally
Study: NCT02365532
Drug: Placebo to match dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to match dofetilide capsules administered orally
Study: NCT02365532
Drug: Dofetilide
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dofetilide 500 μg capsules administered orally according to the current prescribing information
Study: NCT02172222
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no